Four-Year Data on New Drug for Early AD Positive
Research Report
Rest of 2025 Rich With Catalysts for Immunotherapy Co.
Research Report
New Drug for Early AD Shown to be Efficacious, Safe
Research Report
Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal
New Therapy for AATD Could be Best in Class
Research Report
Share Price Appreciation of Biotech Due Over Next Six Months
Research Report
Biotech Company Finds High-Impact Alzheimer's Therapy in Europe
Immunotherapy Company Finds Rare Cancer Breakthrough in U.S.
OS Therapies Inc. (OSTX:NYSEAMERICAN) announced that its lead drug OST-HER2 was granted Orphan Drug Designation by the FDA for osteosarcoma. Read how the designation could accelerate development and create new investor interest.Biotech Co. Has Promising AI-Accelerated Pipeline
Research Report
Rakovina Therapeutics Inc. (RKV:TSX.V) recently gained analyst coverage from First Berlin Equity Research. Read on to see why this company rates the stock a Buy. Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results
Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) is gaining attention with strong Phase 3 results for its lead CNS candidate, brilaroxazine. Here's what analysts are seeing in its long-term potential.Ascending Dose Trial of FABP5 Inhibitor to Read Out Soon
Research Report
Meanwhile, a representative from the company advancing the small molecule in the clinic is slated to speak about it at a conference this week, noted a D. Boral Capital report. Regenerative Medicine Firm OK'd To Advance Trial in T1D
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says the Data Safety Monitoring Board supports the ongoing evaluation of the biotech's Cell Pouch Bio-hybrid Organ in this indication.Cell Pouch Co. Peer Aborts Program Using Like Device
Research Report
The implications for Cell Pouch, an implantable cell delivery vehicle, and the biotech behind it are positive, noted a Leede Financial Inc. report. New Jersey Pharma Co. Shares Positive Pediatric Study
Research Report
Aquestive Therapeutics Inc. (AQST:NASDAQ) recently reported that it completed New Drug Application (NDA) submission for Anaphylm and positive pediatric study data for the non-device-based epinephrine product candidate, noted an H.C. Wainwright & Co. research note. Clean Tech Co. Achieves Record-Breaking Revenue for Exceptional Growth
BioLargo Inc. (BLGO:OTCQX) announced in its annual report that in 2024 it saw record revenues and an increase of 45% over the year before. Read why an expert and an analyst both like this clean technology company's story.GMP Production of Exosomes Slated for Later This Year
Research Report
This is a next big step for the biotech in moving its investigational exosome therapy for chronic inflammation into the clinic, noted a D. Boral Capital report. 
Streetwise Key Charts
